NO20021692L - Purinderivater - Google Patents

Purinderivater

Info

Publication number
NO20021692L
NO20021692L NO20021692A NO20021692A NO20021692L NO 20021692 L NO20021692 L NO 20021692L NO 20021692 A NO20021692 A NO 20021692A NO 20021692 A NO20021692 A NO 20021692A NO 20021692 L NO20021692 L NO 20021692L
Authority
NO
Norway
Prior art keywords
purine derivatives
purine
derivatives
Prior art date
Application number
NO20021692A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021692D0 (no
Inventor
Sandra Marina Monaghan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20021692D0 publication Critical patent/NO20021692D0/no
Publication of NO20021692L publication Critical patent/NO20021692L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
NO20021692A 1999-10-14 2002-04-10 Purinderivater NO20021692L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924363.6A GB9924363D0 (en) 1999-10-14 1999-10-14 Purine derivatives
PCT/IB2000/001444 WO2001027130A1 (en) 1999-10-14 2000-10-06 Purine derivatives

Publications (2)

Publication Number Publication Date
NO20021692D0 NO20021692D0 (no) 2002-04-10
NO20021692L true NO20021692L (no) 2002-04-10

Family

ID=10862760

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021692A NO20021692L (no) 1999-10-14 2002-04-10 Purinderivater

Country Status (50)

Country Link
US (1) US6350735B1 (pl)
EP (1) EP1220863B1 (pl)
JP (1) JP3994007B2 (pl)
KR (1) KR20020037774A (pl)
CN (1) CN1151167C (pl)
AP (1) AP1442A (pl)
AR (1) AR023275A1 (pl)
AT (1) ATE238336T1 (pl)
AU (1) AU768308B2 (pl)
BG (1) BG106569A (pl)
BR (1) BR0011776A (pl)
CA (1) CA2387531C (pl)
CO (1) CO5251399A1 (pl)
CR (1) CR6584A (pl)
CZ (1) CZ20021223A3 (pl)
DE (1) DE60002356T2 (pl)
DK (1) DK1220863T3 (pl)
DZ (1) DZ3159A1 (pl)
EA (1) EA004655B1 (pl)
EC (1) ECSP003712A (pl)
EE (1) EE200200193A (pl)
ES (1) ES2193990T3 (pl)
GB (1) GB9924363D0 (pl)
GE (1) GEP20043269B (pl)
GT (1) GT200000172A (pl)
HK (1) HK1047110B (pl)
HN (1) HN2000000204A (pl)
HU (1) HUP0203483A2 (pl)
IL (1) IL146342A0 (pl)
IS (1) IS6165A (pl)
MA (1) MA26828A1 (pl)
MX (1) MXPA02003812A (pl)
MY (1) MY136242A (pl)
NO (1) NO20021692L (pl)
NZ (1) NZ515323A (pl)
OA (1) OA12059A (pl)
PA (1) PA8503501A1 (pl)
PE (1) PE20010755A1 (pl)
PL (1) PL354932A1 (pl)
PT (1) PT1220863E (pl)
SI (1) SI1220863T1 (pl)
SK (1) SK4842002A3 (pl)
SV (1) SV2002000198A (pl)
TN (1) TNSN00202A1 (pl)
TR (1) TR200200985T2 (pl)
UA (1) UA66945C2 (pl)
UY (1) UY26397A1 (pl)
WO (1) WO2001027130A1 (pl)
YU (1) YU88901A (pl)
ZA (1) ZA200202849B (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
EP1395287A1 (en) * 2001-05-25 2004-03-10 Pfizer Inc. An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
WO2003029264A2 (en) * 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
ATE381336T1 (de) * 2002-04-10 2008-01-15 Univ Virginia Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US20050033044A1 (en) * 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1778712B1 (en) * 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2006134487A1 (en) * 2005-06-15 2006-12-21 Pfizer Limited 3-phenylazetidine derivatives as dopamine agonists
CN100352823C (zh) * 2005-08-19 2007-12-05 浙江车头制药有限公司 一种腺嘌呤衍生物的制备方法
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007092936A2 (en) * 2006-02-08 2007-08-16 University Of Virginia Patent Foundation Method to treat gastric lesions
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
DE602007013441D1 (de) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5536419A (en) * 1978-09-08 1980-03-14 Yamasa Shoyu Co Ltd 2-substituted adenosine derivative and its preparation
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
BR9914526A (pt) * 1998-10-16 2001-07-03 Pfizer Derivados de adenina

Also Published As

Publication number Publication date
AU768308B2 (en) 2003-12-04
ATE238336T1 (de) 2003-05-15
HN2000000204A (es) 2001-06-21
CN1151167C (zh) 2004-05-26
DK1220863T3 (da) 2003-08-11
NO20021692D0 (no) 2002-04-10
OA12059A (en) 2006-05-03
UA66945C2 (uk) 2004-06-15
AR023275A1 (es) 2002-09-04
SK4842002A3 (en) 2003-06-03
DE60002356D1 (de) 2003-05-28
UY26397A1 (es) 2001-05-31
ZA200202849B (en) 2003-06-25
CA2387531A1 (en) 2001-04-19
PT1220863E (pt) 2003-07-31
ES2193990T3 (es) 2003-11-16
PA8503501A1 (es) 2002-02-21
CN1358192A (zh) 2002-07-10
WO2001027130A1 (en) 2001-04-19
EA200101107A1 (ru) 2002-10-31
MA26828A1 (fr) 2004-12-20
GB9924363D0 (en) 1999-12-15
EA004655B1 (ru) 2004-06-24
MXPA02003812A (es) 2002-09-30
EP1220863B1 (en) 2003-04-23
PE20010755A1 (es) 2001-07-17
TR200200985T2 (tr) 2002-10-21
CA2387531C (en) 2006-12-05
AP2002002478A0 (en) 2002-06-30
BG106569A (en) 2002-12-29
CO5251399A1 (es) 2003-02-28
HK1047110A1 (en) 2003-02-07
PL354932A1 (pl) 2004-03-22
US6350735B1 (en) 2002-02-26
HUP0203483A2 (hu) 2003-02-28
CR6584A (es) 2004-01-14
SV2002000198A (es) 2002-02-05
EP1220863A1 (en) 2002-07-10
IS6165A (is) 2001-11-16
AP1442A (en) 2005-06-29
AU7548800A (en) 2001-04-23
DZ3159A1 (fr) 2001-04-19
KR20020037774A (ko) 2002-05-22
DE60002356T2 (de) 2004-02-19
NZ515323A (en) 2003-10-31
MY136242A (en) 2008-08-29
ECSP003712A (es) 2002-05-23
IL146342A0 (en) 2002-07-25
BR0011776A (pt) 2002-03-12
GT200000172A (es) 2002-04-05
HK1047110B (zh) 2005-03-04
YU88901A (sh) 2004-09-03
TNSN00202A1 (fr) 2005-11-10
JP3994007B2 (ja) 2007-10-17
JP2003511459A (ja) 2003-03-25
SI1220863T1 (en) 2003-10-31
EE200200193A (et) 2003-06-16
CZ20021223A3 (cs) 2003-05-14
GEP20043269B (en) 2004-06-25

Similar Documents

Publication Publication Date Title
ATE321065T1 (de) Purin-derivate
DK1220863T3 (da) Purinderivater
EE200100681A (et) Puriinderivaadid
NO20010743D0 (no) Antivirale indoloksoacetyl-piperazin-derivater
DE60119492D1 (de) Purinderivate
DK1296996T3 (da) Purinderivater
DE60009747D1 (de) Admantan-derivate
ATE293104T1 (de) Thiazolylamid-derivate
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
ATE257148T1 (de) Propargyletherderivate
ATE273272T1 (de) Mevinolinderivate
ATE374747T1 (de) Monofluoralkylderivate
ATE254598T1 (de) 4-hydroxybiphenylhydrazid-derivate
ATE293592T1 (de) Resorcinderivate
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
DE59909774D1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate
DK1090019T3 (da) Adenosinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application